|Day's range||53.47 - 53.47|
|52-week range||53.47 - 62.76|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.
Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.